Reports Q4 revenue $1.15M, consensus $1.39M. “Our commercial momentum is building, and that progress is now being reflected in our topline results,” said Steve Lisi, chairman and CEO. “With LungFit PH now installed and in regular use at more than 45 hospitals nationwide, awareness is accelerating. Clinicians and administrators are increasingly recognizing the advantages of our cylinder-free system compared to conventional nitric oxide delivery methods.”
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XAIR:
- Options Volatility and Implied Earnings Moves Today, June 17, 2025
- Beyond Air submits FDA PMA supplement for LungFit PH
- Options Volatility and Implied Earnings Moves This Week, June 16 – June 20, 2025
- XAIR Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Beyond Air granted U.S. patent for gaseous nitric oxide delivery